Chronic Type B Dissection, better with endoprosthesis than with medical treatment

Original title: The results of stent graft versus medication therapy for chronic type B dissection Reference: Xin Jia et al. J Vasc Surg 2013;57:406-14

In many institutions patients with Chronic Stanford Type B Aortic Dissection is most often treated medically, and the thoracic endovascular aortic repair implant TEVAR or the surgical procedure are reserved for those who evolve with complications (persistent pain, expansion of false lumen, visceral or peripheral ischemia). 

Even though these complications may not present, the prognosis for these patients continues to be around 30% mortality at 2 years. This prospective study included 303 consecutive patients with chronic type B aortic dissection that received, following medical criteria, optimal medical therapy (OMT) (95 patients) or thoracic endovascular aorta repair (TEVAR) (208 patients). There were no significant differences in baseline characteristics between the two groups. The median time between dissection and endoprosthesis was 23 days. 

No deaths occurred during index hospitalization in the two groups. The TEVAR group 2 patients (0,9%) required emergency surgery for retrograde type A dissection, 6 patients (2,9%) had vascular complications, 2 patients (0,9%) presented neurological compromise and 2 patients (0,9%) periprocedural infarction. No patients in the OMT group presented events in 30 days.

Conclusion 

This multicenter, prospective and not randomized study, showed lower mortality with TEVAR in treating chronic type B aortic dissection vs. OMT. However, global mortality showed no differences.

Editorial comment

Follow up was lost in more than 20% of patients in both groups but especially in the OMT group (as expected). This makes it difficult to interpret results at long term, precisely when benefits of precocious intervention should be seen. Beyond this limitation, this study shows a very acceptable complications rate at 30 days with the intervention, which raises questions about the efficiency of the traditional management of these patients.

SOLACI.ORG

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...